Agoracom Blog Home

Archive for the ‘Hollister Biosciences’ Category

8 Small Cap #Cannabis Companies That Will Lead The Next Growth Cycle For The $97 Billion Market By 2026 $AVCN.ca $CBDT.ca $HBOR.ca $HOLL.ca $INNO.ca $SPDR.ca $TBI.ca $TCAN.ca

Posted by AGORACOM-JC at 3:39 PM on Thursday, October 8th, 2020

Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:

  1. Cannabis legalization is gaining momentum around the world.
  2. Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
  3. It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).

So what is this going to translate into?

The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92% (Fortune Business Insights)

WHY WILL THIS TIME BE DIFFERENT?

Big promises, big IR budgets, big hype …. Big Letdown.

That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.

Investors will remember that the same thing happened during the dot-com era.  As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.

But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses.  What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.

The same thing is about to happen to the Cannabis sector

Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.  These are the only known CBD cosmetics backed by clinical trials.

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

For more information about the company, please check out the Avicanna HUB on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:

PatientVisits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows: 

  • Increased CBD treatments from patients suffering increased anxiety;
  • Testing for individuals and families
  • Testing for local businesses and employees 
  • Testing for enterprise level organizations across the country 
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 tests per day
    • At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.

For more information about the company, please check out the Empower HUB on AGORACOM.

Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006.  We thought that would get your attention.

What Do They Do?

HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:

1. Retail Dispensaries

2. Wholesale

3. Cultivation and Processing

HIGHLIGHTS

  • Founded in 2006. One of the oldest and most respected cannabis retailers in California
  • Awarded one of the first six medical cannabis licenses in the USA
  • Operations have generated over $400M in cumulative sales since inception
  • Retail operations command 3% of California’s entire retail market
  • 2020 Financials (Q1 +  Q2)

○       Revenues         $30,800,000

○       Gross Profit     $14,000,000

○       EBITDA            $1,100,000

  • Expected to generate approximately $62M – $65M in sales in 2020
  • Operate California’s only drive-through dispensary 
  • Over 1,300 customers per day in Q2
  • Oakland dispensary is one of the largest retail cannabis locations in the world
  • 2020E Guidance
    • ~$44M Retail Revenue
    •   ~$21M Wholesale Revenue
    • ~$62M – ~65M Total Revenue

For more information about the company, please check out the Harborside Inc  hub on AGORACOM.

Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:

  • Revenues $USD
    • Q1 +317%  YoY to $862,000
    • Q2 +3685% YoY to  $8,500,000
  • TOTAL Q1 AND Q2
    • REVENUE                 $9.4M vs $428K     = + 2096%
    • GROSS PROFIT        $1.2M vs ($133K)   = + 1002%

In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:

Hollister is also the creator of California’s most hash-infused pre-roll HashBone

For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

3 Fully Operating Divisions For Investor Diversification

Innocan has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

  1.  PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
  2. CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
  3. OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

  • Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
  • Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)
  • Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

Superior Management Team

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

  • Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
  • Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
  • Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
  • Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

Together they have built one of the most formidable teams in the small cap cannabis world

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.

  1. SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
  2. SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
  3. SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.

For more information about the company, please check out the Spyder Cannabis  hub on AGORACOM.

Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle. 

  • Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
  • Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
  • Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
  •  Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.

We’ll let these revenue numbers speak for themselves.

  • August 2020 CAD $3,809,000
  • July 2020 CAD $2,340,000
  • June 2020 CAD $2,712,000

The above represents an increase of 19%, over the same period in 2019.

QUARTERLY REVENUE $CAD

  • Q1 $7,600,000 Growth
  • Q2  $12,800,000 Growth 

TOTAL Q1 AND Q2

  • REVENUE  $20,400,000
  •  GROSS PROFIT  $2,154,357

The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.

The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.

For more information about the company, please check out the Thoughtful Brands hub on AGORACOM. 

TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.

  • CAD $24.9M  Revenue Run Rate from 10,000 sq.ft  test facility
  • CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
  • Acquired two California companies,
  • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented 
  • Direct to dispensary model, cutting out the middleman

 REVENUES  $CAD

  • Q1  $906,000
  • Q2  $4,300,000

 TOTAL Q1 AND Q2

  • REVENUE     $5,206,000    
  • GROSS MARGIN $1,920,000

For more information about the company, please check out the TransCanna hub on AGORACOM.

Thanks for reading and discovering these great small cap cannabis companies.  Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small-Cap-Marijuana-Cannabis-Stocks

Hollister Biosciences $HOLL.ca 100% Owned Subsidiary Venom Extracts Achieves Initial $30 Million Revenue Milestone $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:16 AM on Tuesday, October 6th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020
  • 100% owned subsidiary, Venom Extracts achieved the first of two revenue milestones in accordance with the terms of the definitive agreement
  • As a result, the Company will issue 19,740,036 common shares to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share

VANCOUVER, BC , Oct. 6, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (Frankfurt: HOB) (the ” Company “, ” Hollister Cannabis Co .” or ” Hollister “) a diversified cannabis branding company with products in over 230 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce that further to the news release dated March 30 th , 2020, its 100% owned subsidiary, Venom Extracts (” Venom “) has achieved the first of two revenue milestones in accordance with the terms of the definitive agreement that was entered in connection with the acquisition of Venom by the Company (the ” Transaction “).

On September 23 rd , 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020. As a result, the Company will issue 19,740,036 common shares (the ” Earn-Out Shares “) to certain former Venom shareholders at a deemed price of $0.20 per Earn-Out Share. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

“We are very pleased with the performance of the Arizona team in their ability to achieve this key milestone so expeditiously,” shared Carl Saling , CEO of Hollister .

None of the securities to be issued pursuant to the Transaction have been or will be registered under the U.S. Securities Act of 1933, as amended (the ” U.S. Securities Act “), or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Rule 506(b) of Regulation D and/or Section 4(a)(2) of the U.S. Securities Act and applicable exemptions under state securities laws. In addition, the securities issued under an exemption from the registration requirements of the U.S. Securities Act will be “restricted securities” as defined under Rule 144(a)(3) of the U.S. Securities Act and will contain the appropriate restrictive legend as required under the U.S. Securities Act.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

July #Cannabis Sales Surge in 5 Western States – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 5:08 PM on Tuesday, September 8th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 230 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. Revenue generated for the three-month period ended June 30th, 2020 was USD $8.47 million. Learn More

July Cannabis Sales Surge in 5 Western States

  • In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019.
  • Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.
A Detailed Look at Cannabis Sales in California, Oregon, Arizona, Colorado and Nevada

Data provided by BDSA indicates that cannabis sales continued their robust expansion in 5 Western states. During July, the eleventh month after the onset of the vaping crisis and the fifth month of the pandemic impacting the market, sales across the five markets totaled $842.8 million, up 12% from June, which sequential increases of 2% in May and 14% in April. March had spiked to $666.0 million from $579.9 million in February as customers purchased cannabis ahead of store closures and concerns about limitations on access, so clearly cannabis sales are back on track. With the near-term effects of the pandemic now behind us, it’s clear that cannabis demand is surging, even in relatively mature markets, like Oregon and Colorado. Nevada continued to recover as tourism slowly returns, with sales growing 23%. California stood out with 15% sequential growth, while Colorado expanded 13%. Oregon sales climbed 6% and Arizona by 3%, but both of these states had meteoric growth from a year ago. July had one more day than June, which has the effect of adding 3% roughly.

Overall sales growth from a year ago among the five Western markets ranged from 26% in California to as high as 54% in Arizona. Nevada has been impacted by the tourist slowdown but still grew 37% from a year ago. Oregon continued its strong growth, rising 44%, while Colorado grew 35%. Concentrates represented 22-37% of sales by market, below the 26-38% share of sales last August before the vaping crisis hit.

Here is a closer look at each market, as detailed by BDSA:

Arizona

In July 2020, cannabis sales in Arizona’s medical dispensaries reached $94.2 million, growing three percent from June and over 54 percent compared to the previous July. Year-to-date through July, sales have reached $589.2 million, increasing by $194.5 million and 49 percent compared to the same period last year.

Flower sales accounted for nearly 48 percent of overall revenue for the month with $44.8 million in sales, growing one percent from June. Pre-rolled Joints, which are tracked as a separate category, accounted for just under four percent of revenue with $3.5 million in sales. Compared to the previous July, Flower sales increased by 52 percent and Pre-rolled Joints increased by 83 percent.

Concentrate sales accounted for about 37 percent of overall revenues with sales totaling $34.6 million in July, increasing six percent from the trailing month. Vape products, the largest segment of the Concentrates category, generated $21.8 million in sales, accounting for 63 percent of the Arizona Concentrates market and over 23 percent of sales across all categories. Compared to July 2019, sales of Dabbable Concentrates grew by 92 percent, while Vape sales grew by 46 percent.

The Ingestibles category accounted for nearly 11 percent of sales in July with $10 million in revenue for the month. Compared to July 2019 and June 2020, sales in the category grew by 47 percent and by four percent, respectively. In July, the $9.3 million in sales from Edibles generated nearly 93 percent of Ingestibles sales overall, while Sublinguals made up the remaining seven percent. Compared to the previous July, Edibles sales increased by 59 percent and Sublingual sales decreased by 30 percent.

California

BDSA sales reporting for the month of July reflects the state market of 699 licensed dispensary locations and 306 delivery operators.

In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019. Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.

Sales from Flower generated $136.2 million in July 2020, accounting for nearly 41 percent of overall revenues. Compared to the trailing month and July 2019, Flower sales grew by 17 percent and 53 percent, respectively. Pre-rolled Joints, which are tracked as a separate category, accounted for nearly 11 percent of overall July revenues, with $35.6 million in sales.

Concentrates were the second-largest revenue category in July 2020, reaching $101 million in sales and accounting for over 30 percent of total revenue. Compared to the trailing month and July 2019, sales increased by 13 percent and by four percent, respectively. The $76 million in Vape sales accounted for over 75 percent of the Concentrates category and 23 percent of the month’s overall sales revenue.

In July 2020, Ingestibles generated $50.8 million in sales, increasing by 11 percent from the trailing month. Compared to July 2019, sales of Ingestibles grew by nearly 21 percent. Edibles contributed 86 percent of Ingestibles revenue, while Sublinguals made up the remaining 14 percent. Compared to July 2019, the Edibles and Sublinguals categories grew by 32 percent and declined by 22 percent, respectively.

Colorado

July 2020 was another milestone for the Colorado cannabis market. Sales in Colorado’s adult-use and medical dispensaries reached a combined $226.8 million, growing 13 percent from June. Compared to the previous July, sales increased by nearly 35 percent. Adult-use sales grew by 33 percent from July 2019 while medical sales grew by 41 percent. Year-to-date through July, combined channel sales have reached over $1.2 billion, increasing 22 percent from the same period last year.

In July, Flower sales accounted for over 47 percent of total monthly revenues, totaling at $107.2 million. Flower sales increased nearly 11 percent from the trailing month and grew 56 percent from the previous July. Year-to-date sales have increased by 40 percent in the category over the same period last year. Pre-rolled Joints, which are tracked separately from Flower, generated $13.2 million in sales for July 2020, growing 31 percent from July 2019 and increasing 17 percent from the trailing month.

The $66.5 million in Concentrate sales during July 2020 represented an 18 percent increase from the previous year and 15 percent growth from the trailing month. The category accounted for over 29 percent of revenue for the month. Vape products, the largest segment within the Concentrates category, reached $32.9 million in July sales, increasing 19 percent compared to June and four percent from the previous July, respectively. The Vape category accounted almost 50 percent of Concentrates’ revenue and 15 percent of overall sales for the month.

In July 2020, sales from Ingestibles generated $34.7 million, a 27 percent increase from July 2019. Compared to the trailing month, sales in the category grew by 17 percent. Edibles generated $32.7 million in monthly sales revenue, contributing over 94 percent to category sales and 14 percent of total revenue for the month. Sublinguals made up the remaining six percent of Ingestibles sales, totaling $1.9 million for the month.

Nevada

In July, Nevada dispensaries generated $82 million in sales. Compared to July of 2019, sales grew by 37 percent and by nearly 23 percent compared to the trailing month. Year-to-date through July, sales have reached $421.9 million, growing by six percent compared to the same period last year.

Flower sales accounted for nearly 54 percent of overall July 2020 sales. Sales in the category reached $44.1 million for the month, growing 27 percent from June. Pre-rolled Joints, tracked separately from Flower, accounted for nearly 11 percent of July sales, with $8.8 million in revenue. Compared to July 2019, Flower and Pre-rolled Joints sales have increased by 75 percent and by two percent, respectively.

Concentrate sales in July reached $18.3 million, accounting for more than 22 percent of overall revenue for the month. Compared to the trailing month as well as to the previous July, category sales increased by 17 percent. Vape products, the largest segment in the Concentrates category, generated $13.3 million for the month, contributing nearly 73 percent to Concentrates revenue and over 16 percent to total monthly sales.

Sales in the Ingestibles category accounted for 11 percent of all revenues, totaling $9.1 million in July sales and growing by about seven percent from the previous year. Compared to June, category sales grew by 17 percent. Edibles made up 90 percent of the Ingestibles category, reaching $8.2 million in July revenue, and Sublingual sales contributed the remaining ten percent.

Oregon

In July 2020, cannabis sales in Oregon’s medical and adult-use dispensaries reached a combined $106 million. Compared to the trailing month, sales in the Oregon market grew by about six percent, while compared to July 2019, sales grew by 45 percent overall. Year-to-date sales in Oregon have reached $620.3 million, growing by 39 percent compared to the same period in 2019.

Sales of Flower generated $50.3 million in July 2020, accounting for 47 percent of overall revenues. Compared to the trailing month, Flower sales grew by four percent, and compared to July 2019, sales increased by 65 percent. Pre-rolled Joints, which are tracked as a separate category, accounted for nine percent of overall revenues with $9.8 million in sales.

Concentrates generated $27.7 million in July sales. Compared to the trailing month and July 2019, sales in the category increased five percent and just over 25 percent, respectively. Vape products, the largest segment in the Concentrates category, generated $15 million in July, contributing over 54 percent of Concentrates sales and more than 14 percent of total monthly revenue.

In July 2020, Ingestibles generated over $14.6 million in sales, a nine percent increase from the previous month and nearly 25 percent compared to July 2019. Edibles, which made up 83 percent of the Ingestibles category and more than 11 percent of overall monthly sales, generated $12 million in July 2020.

For readers looking for a deeper look at cannabis markets across these five states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how the BDSA GreenEdge Platform can provide you with unlimited access to the most accurate and actionable data and analysis.

Source: https://www.newcannabisventures.com/july-cannabis-sales-surge-in-5-western-states/

VIDEO – Hollister $HOLL.ca Reports Record Q2 Revenues With $8.47M From 300+ Dispensaries In California and Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:28 PM on Tuesday, September 1st, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE). is a multi-state operator with multiple, high-quality products that are now carried in 230 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” + another 80 Arizona dispensaries with some of the best concentrate in the State.  

But given the state of disappointment in the Cannabis industry over the last 15 months, none of that would mean anything without actual results shareholders and the industry could celebrate.  In that regard, Hollister does not disappoint with Q2 numbers coming in as follows:

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

There isn’t a small cap cannabis company that would not cheer for these results – if that was all they had.  These numbers are a company maker.   But Hollister is set to continue growing on several fronts, including a Direct To Consumer model and further big expansion in California.  

Watch this incredible interview with President Alex Somjen.   

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

Hollister Biosciences Inc. $HOLL.ca Reports Second Quarter 2020 Results With $8.47 Million In Revenue $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:25 AM on Monday, August 24th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Multi-state operator and diversified cannabis branding company generates record quarterly revenue and delivers profitable second quarter

  • Revenue generated for the three-month period ended June 30th, 2020 was $8.47 million versus $0.2 million from the second quarter last year, representing significant year over year revenue growth
  • Revenue was primarily generated from the sale of concentrates, pre-rolls and contract manufacturing services

VANCOUVER, BC, Aug. 24, 2020 – Hollister Biosciences Inc. (CSE: HOLL), (OTC: HSTRF), (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona, announces financial results for the second quarter 2020 (ended June 30th, 2020).  All figures in US Dollars unless otherwise stated.

Second Quarter Financial Highlights

  • Revenue generated for the three-month period ended June 30th, 2020 was $8.47 million versus $0.2 million from the second quarter last year, representing significant year over year revenue growth
  • Revenue was primarily generated from the sale of concentrates, pre-rolls and contract manufacturing services
  • Net income for the three-month period ended June 30th, 2020 was $0.3 million compared to a net loss of $2.1 million in the first quarter of 2020

“Our second quarter results are encouraging and in line with our objective to increase revenue and profitability” shared Alex Somjen, President of Hollister Biosciences Inc.  “These financial results are a product of increased brand awareness, strategic M&A and strategic partnerships put in place over the previous six months.”

Operational Highlights and Strategic Objectives for 2020

  • The challenges presented by the COVID-19 pandemic have accelerated Hollister’s plans to roll out direct to consumer delivery
    • The brand will be called “Dreamy Delivery” and the first delivery hub is expected to launch in the fourth quarter of 2020 with statewide delivery anticipated by the end of 2021
  • Design and build-out of Hollister’s 100% owned subsidiary, Venom Extracts, in the Company’s Hollister, CA facility are underway
  • Product development and product launch associated with the Company’s joint venture with Tactical Relief and the Company’s 100% owned subsidiary, Alpha Mind Brands Inc., respectively, are progressing
  • The Company’s partnership with Tommy Chong’s Cannabis is progressing well, with Tommy Chong’s Full Spectrum Elixir now being distributed in 20 dispensaries throughout the state of California by Hollister’s distribution partner Indus Holdings Inc. (CSE: INDS)

“Enormously proud of our teams in Arizona & California.  Our staff continues to overcome obstacles like the global pandemic while posting record revenue numbers. We look forward to continuing to execute on our plans while increasing value for our shareholders.” Said Carl Saling CEO of Hollister Biosciences.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website:www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-inc-reports-second-quarter-2020-results-301116831.html

SOURCE Hollister Biosciences Inc.

Hollister Biosciences $HOLL.ca Closes $1.5 Million Private Placement Financing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:11 PM on Monday, August 10th, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1
  • Announced non-brokered private placement financing by issuance of 17,646,889 units at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000

VANCOUVER, BC, Aug. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, is pleased to announce that it has closed its previously announced non-brokered private placement financing by issuance of 17,646,889 units (the “Units” and each individually, a “Unit“) at a price of $0.085 per Unit for gross proceeds of approximately $1,500,000 (the “Offering“).  

Each Unit is comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant. Each warrant will be exercisable into Share at a price of $0.10 until August 10, 2022.

The Company has paid eligible finders cash commission in the total amount of $108,201.26. The Company has also issued non-transferable compensation options (“Finder’s Options“) to finders to acquire up to a total of 1,272,959 Units (“Finder’s Units“), at a price of $0.085 per Finder’s Unit on or before August 10, 2022. Each Finder’s Unit will consist of one Share and one non-transferable share purchase warrant (the “Finder’s Warrant“). Each Finder’s Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share on or before August 10, 2022.

All securities issued in connection with the Offering are subject to a statutory hold period of four-months and one day ending on December 11, 2020. The Company intends to use the net proceeds of the Offering for the expansion of Venom Extracts, Hollister’s 100% owned subsidiary, into California and for working capital and general corporate purposes.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com 

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The securities issued in connection with the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Biosciences Inc. $HOLL.ca and Heavy Brands Inc. Enter into Letter of Intent for Proposed Joint Venture Agreement $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:16 AM on Wednesday, August 5th, 2020
  • Announced that it’s entered into a letter of intent to manufacture pre-rolls for some of the biggest names in rock and metal music
  • Under the terms of the Agreement, Heavy intends to license its Heavy Grass brand for use by Hollister in connection with branding, production and sale of cannabis products primarily via collaborations with its roster of music artists
  • Hollister will grant to Heavy a limited license for use of its HashBone brand for incorporation into any packaging and/or logo design of products. Heavy will retain ownership of all co-brand designs

VANCOUVER, BC, Aug. 5, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company”, “Hollister Cannabis Co.” or “Hollister”) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona, is pleased to announce that it has entered into a letter of intent (the “LOI”) to complete a Definitive Agreement (the “Agreement”) with Heavy Brands Inc. (“Heavy”), a rock and heavy metal lifestyle cannabis branding company.

Under the terms of the Agreement, Heavy intends to license its Heavy Grass brand for use by Hollister in connection with branding, production and sale of cannabis products primarily via collaborations with its roster of music artists. Hollister will grant to Heavy a limited license for use of its HashBone brand for incorporation into any packaging and/or logo design of products. Heavy will retain ownership of all co-brand designs.

Products will be introduced in time and will include separate product branding. Heavy will lead the marketing initiatives of the new products leveraging their unique access to the live music industry.  

Heavy-Hollister co-brand products will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc. (CSE: INDS), with the first product anticipated to be ready for distribution by October 1, 2020.

When asked about the Agreement, Dez Mitchell, head of Product Development from Heavy shared: “We are so thrilled to begin our partnership with Hollister and cannot wait to launch our first products together this fall.  For our Heavy Grass family, music and cannabis go hand in hand.  We have been fortunate to get to know Carl and his team over the last year and they have proven to uniquely understand our vision.  We are excited to show the world what we’ve been working on together.”

CEO of Hollister Biosciences, Carl Saling, also shared: “Music and cannabis have gone together for so many years; and lately, for the most part, it’s been all connected to rap and hip hop. I have always wanted to bring more attention to cannabis and connect with fans of heavy metal in a truly authentic way.

We have big things in store for our initial launch, and looking forward to many awesome rock and metal collaborations that Hollister and Heavy Grass will be bringing to market.”

About Heavy Brands

Heavy Brands Inc. is a Southern California lifestyle cannabis branding and marketing company building globally recognized cannabis lifestyle brands based in Los Angeles.  It’s flagship brand, Heavy Grass, has grown organically by connecting hard rock and heavy metal fans to cannabis products that speak to their lifestyle.  Additionally, Heavy Grass releases a seasonal line of apparel that is worn by some of the largest rock artists and fans around the world.

Website: https://getheavy.com/

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Hollister Biosciences $HOLL.ca Provides Update on Q2 2020, Generated Record Quarterly Revenue of CDN$ 11.5 Million and Announces Distribution License Renewal $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:05 PM on Tuesday, July 14th, 2020
  • Generated record quarterly revenue of CDN$ 11.5 million,
  • CDN$ 1.375 million in EBITDA
  • Bureau of Cannabis Control officially renewed its cannabis distribution license for the next year through August 2021

VANCOUVER, BC, July 14, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 230 dispensaries throughout California, and over 80 dispensaries throughout Arizona,  is pleased to provide an update on its Q2, 2020 performance as well as announce that the Bureau of Cannabis Control (“BCC“) officially renewed its cannabis distribution license for the next year through August 2021.

Q2 2020 Update

For the period beginning April 1st, 2020 and ending June 30th, 2020, Hollister reports that it generated record quarterly revenue of CDN$ 11.5 million and CDN$ 1.375 million in EBITDA from its product line of pre-rolls, concentrates, distillates, solvent-free bubble hash, pre-packaged flower, tinctures and vape products.  The Company cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by management.

“We are very pleased with our revenue growth year to date.  Sales of cannabis related products have proven to be resilient throughout the COVID-19 pandemic.  We hope to continue to deliver strong results as the year progresses” stated Carl Saling, CEO.

About the BCC

The Bureau of Cannabis Control is the lead agency in regulating commercial cannabis licenses for medical and adult-use cannabis in California. The BCC is responsible for licensing retailers, distributors, testing laboratories, microbusinesses, and temporary cannabis events. A distributor (Type 11) licensee is responsible for transporting cannabis goods between licensees, arranging for testing of cannabis goods, and conducting the quality assurance review of cannabis goods to ensure compliance with all packaging and labeling requirements. A licensed distributor may only distribute cannabis goods, cannabis accessories, and licensees’ branded merchandise or promotional materials.

“Our distribution license is a critical component to our California operation, and we are honored to have had our license renewed by the BCC” stated Carl Saling, CEO.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Biosciences Inc. $HOLL.ca and Allied Corp. sign Definitive Agreement for Distribution of Products Under Veteran Based Brand: Tactical Relief™ $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:12 AM on Friday, June 26th, 2020
  • Announced definitive agreement with Allied Corp. to manufacture and distribute throughout California products targeted at veterans and first responders under the brand Tactical Relief ™
  • The first products to be manufactured will feature products that are recognized for their medicinal properties in the treatment of Post Traumatic Stress Disorder (PTSD)

VANCOUVER, British Columbia, June 26, 2020 — Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB) (the “Company” or “Hollister”) is pleased to announce that further to the press release dated February 7th, 2020, through it’s subsidiary, Hollister Cannabis Co.  has on June 22nd, 2020 signed a definitive agreement (the “Agreement”) to bring to market with Allied Corp. (“Allied”) a pipeline of products that are targeted towards helping veterans and first responders. These products will be brought to market under the brand Tactical Relief™, a veteran-founded hemp-based CBD oil brand owned by Allied Corp. (OTCQB: ALID).

Branded under Tactical Relief™, the first products to be manufactured will feature products that are recognized for their medicinal properties in the treatment of Post Traumatic Stress Disorder (PTSD). True to Hollister’s mission, the products will be crafted in small, artisanal batches for optimal quality and made from premium California-grown cannabis.

Under the terms of the Agreement, Allied will contribute the Tactical Relief™ brand support including use of trademark, artwork, logos and package design for a series of products. On an ongoing basis, Allied will be financially responsible for all marketing design and support. Hollister will be responsible for all aspects of production and procurement of underlying materials. Hollister will also be responsible for all costs associated with distribution and sales support.  All production of cannabis products will take place under Hollister’s supervision and licenses. Allied and Hollister will further explore the development and marketing of additional products, as well as expanding into additional regions within the United States over the coming years.

The new Tactical Relief™ products will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc. (CSE: INDS), and is anticipated to be in retail locations throughout California within quarter three of 2020. An estimated 5% of net profits from all sales will be donated to charity.  The remaining revenue generated from the sale of the products will be shared 60:40 between Hollister and Allied.

“This partnership is one that unites two powerful companies in the cannabis space with one common mission: to help veterans and first responders change the way they manage PTSD and TBI. This is a huge shift that has to happen nationwide. This partnership is the start of that shift,” said Adam Smith, VP Natural Health at Allied Corp.

Carl Saling, Hollister’s CEO stated: “We are thrilled to be working with Allied Corp. to bring much needed relief to our amazing veterans and 1st responders with PTSD and other ailments. This is a very important mission for Hollister to be able to have a huge impact on our veteran’s lives.”

About the Tactical Relief™  Brand

Led by a Green Beret and trainer of law enforcement, the Tactical Relief™ brand creates, promotes and sells high quality and patriotic CBD oils throughout the country. Allied’s CBD oils are full spectrum and are currently made from the highest quality hemp grown in Kentucky. Adam Smith (VP of Natural Health for Allied Corp.) is a Green Beret with nearly 17 years in service and experienced firsthand how CBD can help veterans and active-duty (military and first responders) ease their physical and mental stress due to post traumatic stress disorder and traumatic brain injury. Tactical Relief™ is on a mission to end the stigma around hemp and cannabis products, and to provide relief to as many service members as possible.

Website: https://tacticalrelief.com/

About Allied Corp.

Allied Corp. is an international medical cannabis production company with a mission to address today’s medical issues with a primary focus on Post Traumatic Stress Disorder in veterans and first responders. Allied helps those who have served by researching, developing and producing targeted cannabinoid health solutions for those who need them. Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

For more information on Allied Corp., visit www.allied.health

Investor Relations for Allied:
[email protected]
1-877-255-4337

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a California based vertically integrated cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality California-grown cannabis and hemp products. Hollister uses a vertically integrated, high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker.”

Website: www.hollistercannabisco.com

HOLLISTER BIOSCIENCES INC.:

Company Contact:

[email protected]
Tel: 604-961-0296

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

Hollister Bioscience’s $HOLL.ca 100% Owned Subsidiary #Venom Extracts Generates Record Monthly Revenue of $3.75 million CDN in May 2020 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:18 AM on Thursday, June 11th, 2020
  • For the month of May 2020, Venom reports that it generated record revenue of CDN$ 3.75 million from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges, representing the highest revenue Venom has achieved in a single month
  • As compared to May 2019, Venom’s revenue increased 163%. 

VANCOUVER, BC, June 11, 2020 - Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) ( FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that its 100% owned subsidiary Venom Extracts (“Venom“) generated record revenue and EBITDA for the month of May 2020. 

For the month of May 2020, Venom reports that it generated record revenue of CDN$ 3.75 million from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges, representing the highest revenue Venom has achieved in a single month.  As compared to May 2019, Venom’s revenue increased 163%.  The Company cautions that revenue figures have not yet been audited and are based on reports prepared by Venom management.

“We are firing on all cylinders here at Venom” shared Jake Cohen, Founder of Venom Extracts.  “Having our best month ever in terms of revenue and EBITDA speaks to the resilience of our business model in the face of these uncertain times as well as the healthy customer demand for our product line.”

“We are very excited to see these record monthly revenues. We are looking forward to replicating Venom’s business model in our California facilities and beyond.” shared Carl Saling, CEO of Hollister Biosciences Inc.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com